Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06444542
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2024-05-14
Brief Title:
Understanding Patient Preference on Colorectal Cancer Screening Options-PSU
Sponsor:
Milton S Hershey Medical Center
Organization:
Milton S Hershey Medical Center
Study Overview
Official Title:
Understanding Patient Preference on Colorectal Cancer Screening Options
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
U-Screen
Brief Summary:
There are significant barriers to colorectal cancer screening within underserved populations due to the cost accessibility and acceptability of screening methods Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis The primary aim of this study is to examine whether the availability of a blood-based screening option which can be done at the point of service and is familiar to patients will improve patient compliance to recommended CRC screening
Detailed Description:
Scientific Background and Gaps Colorectal cancer CRC is the third most common cancer type and the second leading cause of cancer death in the United States The lethal nature of CRC is attributable to its being largely asymptomatic during the early stages and the lack of curative treatment options for patients with progressive disease Early detection by screening significantly reduces mortality from CRC however many people are not up to date with screening with overall screening rates under 70 Furthermore about a quarter of age-eligible adults 271 million have never been screened for CRC A recent study found that not being up to date with screening was associated with an approximate 3-fold risk for CRC-related mortality Despite many years of effort and funding support CRC screening rates have plateaued with a considerable segment of the population remaining unscreened The percentage of age-eligible adults who were up to date with CRC screening only increased by 14 42 million from 674 in 2016 to 688 in 2018 Compliance with CRC screening is particularly poor among medically underserved populations including those with low income and racialethnic minority populations There are significant barriers to screening within underserved populations due to the cost accessibility and acceptability of screening methods To date there are many well-established CRC screening modalities and can include invasive and non-invasive options that detect both polyps and cancer or cancer alone Colonoscopy is considered the gold standard for CRC screening and remains the dominant screening modality in the US However due to the invasiveness perception of discomfort and embarrassment logistical challenges eg lack of transportation time off of work cost and potential risks the uptake of colonoscopy is low For patients unwilling to screen with colonoscopy non-invasive stool-based testing can shift CRC detection to earlier and more curable stages However the compliance of stool-based testing is suboptimal due to the cultural stigma surrounding sample collection techniques and the inconvenience of returning the kit for testing Increasing patient compliance and adherence to screening is critical to improving CRC outcomes Patient-friendly approaches that minimize stress and discomfort for the patient are needed to enhance screening compliance and achieve an early diagnosis A blood-based screening option can improve CRC screening uptake and adherence at FQHCs and ultimately eliminate unnecessary cancer disparities
Previous Data Patient compliance is a major barrier to achieving universal screening Blood-based testing can offer an alternative for patients who fail to comply with other screening modalities Blood tests are non-invasive compared to colonoscopy and individuals are more willing to have a blood test than take a stool sample at home In a cross-sectional survey of 100 individuals 91 ranked a blood-based test as their first or second choice of screening 58 for the first choice 10 tied and 23 for the second choice compared with colonoscopy sigmoidoscopy or stool-based tests Furthermore over two-thirds of minority respondents n62 chose a blood-based screening test as their first choice for future screening Blood-based screening test also presents an opportunity to overcome challenging barriers such as transportation and time off from work limiting screening participation
Study Rationale A key to improving screening participation is patient acceptance of the testing method Indeed all the screening modalities have benefits over time and compliance to testing is essential for successful screening A blood-based screening test can easily be part of a routine clinic visit and the patient can complete the test while is still at the clinic Patients are accustomed to providing blood samples for other screening tests such as cholesterol screening and the use of blood-based CRC screening test is likely more in line with a patients expectations of medical care On January 19 2021 the Centers for Medicare and Medicaid Services announced that the blood-based biomarker test is an appropriate CRC screening once every 3 years for Medicare patients when performed in a CLIA-certified laboratory ordered by a treating physician and the blood-based biomarker screening test has a sensitivity greater than or equal to 74 and a specificity greater than or equal to 90 in the detection of CRC
The last decades have seen many discovery studies identifying promising biomarkers of CRC Improving testing methods for blood-based CRC testing have been developed and implemented in clinical settings as well The first blood-based CRC screening test SEPT9 DNA Epi proColon was approved by the FDA in 2016 for persons at average risk for CRC who have chosen not to undergo screening by existing guideline-recommended methods This study will offer a lab-developed Guardant SHIELD blood-based CRC screening test to patients who failed to complete a stool-based screening test or a colonoscopy six months after receiving an order from their providers The Guardant SHIELD blood-based screening test will be free to the patients with an order from their providers The Guardant SHIELD test is a multimodal blood-based colorectal neoplasia detection assay incorporating ctDNA circulating tumor DNA assessment of somatic mutations and tumor-derived methylation and fragmentomic patterns to maximize early-stage CRC detection sensitivity Overall the Guardant SHIELD blood-based test has a CRC sensitivity of 91 and a specificity of 94 meeting the Centers for Medicare and Medicaid Services requirement 74 for sensitivity and 90 for specificity All the blood samples collected in this study will be processed at the CLIA-certified Guardant Health Laboratory
Compliance by age-eligible patients is essential to the success of any screening program However the acceptance by health care providers and the health care system is also critical and especially colonoscopy remains the dominant modality for CRC in the US Applying the current state of research evidence to health care involves fostering the adoption implementation spread and sustainability of new evidence-based interventions to care Furthermore transferring effective interventions into real-world settings and maintaining them is a complicated long-term process that requires complex phases of intervention diffusion In this study we will examine the inclusion of a blood-based screening option to increase patient compliance with CRC screening while developing implementation strategies to facilitate the adoption of a new blood-based screening test at primary care clinics
Previous Data Patient compliance is a major barrier to achieving universal screening Blood-based testing can offer an alternative for patients who fail to comply with other screening modalities Blood tests are non-invasive compared to colonoscopy and individuals are more willing to have a blood test than take a stool sample at home In a cross-sectional survey of 100 individuals 91 ranked a blood-based test as their first or second choice of screening 58 for the first choice 10 tied and 23 for the second choice compared with colonoscopy sigmoidoscopy or stool-based tests Furthermore over two-thirds of minority respondents n62 chose a blood-based screening test as their first choice for future screening Blood-based screening test also presents an opportunity to overcome challenging barriers such as transportation and time off from work limiting screening participation
Study Rationale A key to improving screening participation is patient acceptance of the testing method Indeed all the screening modalities have benefits over time and compliance to testing is essential for successful screening A blood-based screening test can easily be part of a routine clinic visit and the patient can complete the test while is still at the clinic Patients are accustomed to providing blood samples for other screening tests such as cholesterol screening and the use of blood-based CRC screening test is likely more in line with a patients expectations of medical care On January 19 2021 the Centers for Medicare and Medicaid Services announced that the blood-based biomarker test is an appropriate CRC screening once every 3 years for Medicare patients when performed in a CLIA-certified laboratory ordered by a treating physician and the blood-based biomarker screening test has a sensitivity greater than or equal to 74 and a specificity greater than or equal to 90 in the detection of CRC
The last decades have seen many discovery studies identifying promising biomarkers of CRC Improving testing methods for blood-based CRC testing have been developed and implemented in clinical settings as well The first blood-based CRC screening test SEPT9 DNA Epi proColon was approved by the FDA in 2016 for persons at average risk for CRC who have chosen not to undergo screening by existing guideline-recommended methods This study will offer a lab-developed Guardant SHIELD blood-based CRC screening test to patients who failed to complete a stool-based screening test or a colonoscopy six months after receiving an order from their providers The Guardant SHIELD blood-based screening test will be free to the patients with an order from their providers The Guardant SHIELD test is a multimodal blood-based colorectal neoplasia detection assay incorporating ctDNA circulating tumor DNA assessment of somatic mutations and tumor-derived methylation and fragmentomic patterns to maximize early-stage CRC detection sensitivity Overall the Guardant SHIELD blood-based test has a CRC sensitivity of 91 and a specificity of 94 meeting the Centers for Medicare and Medicaid Services requirement 74 for sensitivity and 90 for specificity All the blood samples collected in this study will be processed at the CLIA-certified Guardant Health Laboratory
Compliance by age-eligible patients is essential to the success of any screening program However the acceptance by health care providers and the health care system is also critical and especially colonoscopy remains the dominant modality for CRC in the US Applying the current state of research evidence to health care involves fostering the adoption implementation spread and sustainability of new evidence-based interventions to care Furthermore transferring effective interventions into real-world settings and maintaining them is a complicated long-term process that requires complex phases of intervention diffusion In this study we will examine the inclusion of a blood-based screening option to increase patient compliance with CRC screening while developing implementation strategies to facilitate the adoption of a new blood-based screening test at primary care clinics
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None